| hepatitis c virus type 1b (ii) infection in france and italy. collaborative study group. | to analyze the distribution of hepatitis c virus (hcv) genotypes among patients positive for antibody to hcv (anti-hcv) according to age, severity of liver disease, and duration of infection; to investigate the influence of hcv genotypes on response to interferon-alpha therapy; and to study hcv viremia levels in relation to genotypes and severity of liver disease. | 1995 | 7810932 |
| high prevalence of hepatitis c virus type 1b in italian patients with porphyria cutanea tarda. | a strong association between sporadic porphyria cutanea tarda and chronic hepatitis c virus infection was recently described in italy, france and spain. | 1997 | 9513830 |
| hepatitis c virus genotypes and clinical features in hepatitis c virus-related mixed cryoglobulinemia. | mixed cryoglobulinemia is a systemic disease, almost always associated with hepatitis c virus infection and characterized by purpura and cutaneous vasculitis, asthenia, arthralgias, and often renal and neurological involvement. no significant differences have been described to date in mixed cryoglobulinemia patients with type 1, 2, or 3 hepatitis c virus infection with respect to symptoms, while a higher prevalence of genotype 2a has been reported in patients without clinical and biochemical sig ... | 1998 | 9689550 |
| a simple pcr with different 3' ends of the third primer for detection of defined point mutations: hcv genotyping as an example. | in this article, we describe a useful modification of the polymerase chain reaction for amplification applicable to hepatitis c virus genotyping and determination of its subtypes. the method is fast, cheap and simple for detection of any known point mutation, and could be used in every laboratory with experience in polymerase chain reaction technique. we could differentiate hepatitis c virus subtype 1b from other subtypes and 2b from 2a and other subtypes as well. we could also differentiate hep ... | 1998 | 9806465 |
| improved correlation between multiple mutations within the ns5a region and virological response in european patients chronically infected with hepatitis c virus type 1b undergoing combination therapy. | studies from japan showed that hcv-1b isolates with at least four amino acid changes within ns5a2209-2248 compared with the prototype sequence hcv-j are more sensitive to interferon than isolates with a prototype sequence. however, the data were not unequivocally confirmed in studies from other geographical areas. these discrepancies may be explained by differences in the prevalence of multiple mutations within the ns5a2209-2248 and/or the treatment efficacy. | 1999 | 10406177 |
| evidence for sequence selection within the non-structural 5a gene of hepatitis c virus type 1b during unsuccessful treatment with interferon-alpha. | resistance of the hepatitis c virus (hcv) to interferon-alpha (ifn-alpha) therapy in patients with hepatitis c may be genetically controlled by an ifn sensitivity-determining region (isdr) within the non-structural 5a (ns5a) gene. to assess whether hcv 1b strains carrying a 'resistant' type of isdr are selected during unsuccessful ifn therapy, we analysed the evolution of the ns5a quasispecies, as detected by the clonal frequency analysis technique, and of the isdr sequence by nucleotide sequenc ... | 1999 | 10607252 |
| positively selected amino acid sites in the entire coding region of hepatitis c virus subtype 1b. | to predict the amino acid sites important for the clearance of hepatitis c virus (hcv) subtype 1b in vivo, positively selected amino acid sites were detected by analyzing the sequence data collected from the international dna databank. the rate of nonsynonymous substitutions per nonsynonymous site was compared with that of synonymous substitutions per synonymous site for each codon site in the entire coding region. as a result, 13 out of 3010 amino acid sites were found to be positively selected ... | 2001 | 11591474 |
| factors predictive of response to interferon-alpha therapy in hepatitis c virus type 1b infection. | interferon-alpha (ifn-alpha) has been used to treat hepatitis c virus (hcv)-induced infection but has been effective in only about half of all patients. it is suggested that the different responses to ifn-alpha treatment in hcv infection may be influenced by hcv genotypes, hcv rna titer at the beginning of ifn-alpha therapy, and the sequences of the interferon sensitivity determining region (isdr). however, there have also been reports showing that these have no relation to an ifn-alpha effect. ... | 2002 | 11857525 |
| comparative sequence analysis of the core protein and its frameshift product, the f protein, of hepatitis c virus subtype 1b strains obtained from patients with and without hepatocellular carcinoma. | the core protein of hepatitis c virus (hcv) has been implicated in hepatocarcinogenesis. in order to determine whether there is a correlation between mutations of the core protein and the development of hepatocellular carcinoma (hcc), the core protein-coding sequence of the viral genome of hcv subtype 1b (hcv-1b) obtained from patients with and without hcc was analyzed. we found that 12 (40.0%) of 30 hcv-1b isolates from patients with hcc but none of 29 isolates from patients without hcc had a p ... | 2002 | 12354856 |
| mutations in the ns5a and e2-pephd region of hepatitis c virus type 1b and correlation with the response to combination therapy with interferon and ribavirin. | nonstructural 5a (ns5a) and the second envelope (e2) proteins of hepatitis c virus (hcv) have the potential to block interferon (ifn)-induced rna-dependent protein kinase (pkr) and may therefore interfere with the response to ifn therapy, but controversy still exists regarding the relevance of this. this study aimed to assess whether mutations in these regions correlated with the response to combination therapy, ifn and ribavirin. pretreatment parameters were analysed in 57 hcv-1b patients who h ... | 2003 | 12614464 |
| identification of hepatitis c virus (hcv) subtype 1b strains that are highly, or only weakly, associated with hepatocellular carcinoma on the basis of the secondary structure of an amino-terminal portion of the hcv ns3 protein. | the ns3 protein of hepatitis c virus subtype 1b (hcv-1b) isolates obtained from 89 patients with hepatocellular carcinoma (hcc) and 78 patients without hcc were analyzed. on the basis of the secondary structure of the amino-terminal 120 residues of ns3, hcv-1b isolates were classified into group a, group b, and an indeterminate group, each of which was further divided into a number of subgroups, such as a1-1, a1-2, a2-1, a2-2, b1-1, b1-2, b2-1, b2-2, c-1, c-2, and c-3. hcv-1b isolates of subgrou ... | 2003 | 12843009 |
| sustained virological response in hepatitis c virus type 1b infected patients is predicted by the number of mutations within the ns5a-isdr: a meta-analysis focused on geographical differences. | there is growing evidence that the response of hepatitis c virus (hcv) genotype 1b infected patients towards interferon (ifn) therapy is influenced by the number of mutations within the carboxy terminal region of the ns5a gene, the interferon sensitivity determining region (isdr). | 2004 | 15306598 |
| mutations in the e2-pephd region of hepatitis c virus type 1b in patients with hepatocellular carcinoma. | an interaction between the protein kinase (pkr)-eif2-alpha phosphorylation homology domain (pephd) within the e2 protein of hepatitis c virus (hcv) and cell protein kinase (pkr) may affect the control of protein synthesis and cell growth. in an attempt to investigate the genetic variability of the e2-pephd domain in hepatocellular carcinoma (hcc), we studied sera and liver tissues from hcc patients. the partial e2-pephd region was analysed by direct sequencing of the sera of 47 hccs in cirrhotic ... | 2005 | 15850464 |
| prediction of efficient virological response to pegylated interferon/ribavirin combination therapy by ns5a sequences of hepatitis c virus and anti-ns5a antibodies in pre-treatment sera. | a considerable number of patients infected with hepatitis c virus subtype 1b (hcv-1b) do not respond to pegylated interferon/ribavirin combination therapy. in this study we explored a useful factor(s) to predict treatment outcome. a total of 47 hcv-1b-infected patients were treated with pegylated interferon/ ribavirin for 48 weeks. sera of the patients were examined for the entire ns5a sequence of the hcv genome, hcv rna titers and anti-ns5a antibodies. according to their responses, the patients ... | 2007 | 17446688 |
| distinctive pattern of sequence polymorphism in the ns3 protein of hepatitis c virus type 1b reflects conflicting evolutionary pressures. | analysis of complete polyprotein-encoding sequences of hepatitis c virus genotype 1b (hcv-1b) showed evidence not only of past purifying selection but also of abundant slightly deleterious non-synonymous variants subject to ongoing purifying selection. the ns3 protein (with protease and ntpase/helicase activity) revealed less evidence of purifying selection acting on the cytotoxic t cells (ctl) epitopes than did the other proteins, whereas outside the ctl epitopes ns3 was more conserved than the ... | 2008 | 18632963 |
| [influence of f protein of hepatitis c virus subtype 1b inhibits on human hepatocellular carcinoma hepg2 cell apoptosis]. | to investigate the effects of f protein of hepatitis c virus subtype 1b on the apoptosis of human hepatocellular carcinoma hepg2 cells. | 2009 | 19731535 |
| antiviral effects of peginterferon alpha-2b and ribavirin following 24-week monotherapy of telaprevir in japanese hepatitis c patients. | background/aims: anemia is commonly observed as a side effect in a treatment with protease inhibitors combined with peginterferon alpha and ribavirin for hepatitis c virus infection. this study assessed the safety, tolerability, viral kinetics, and selection of variants in telaprevir monotherapy for 24 weeks, and outcomes of the off-study treatment with peginterferon alpha-2b and ribavirin among japanese female patients at a median age of 54 years who were difficult to treat with the standard th ... | 2011 | 21556829 |
| virological response and safety of 24-week telaprevir alone in japanese patients infected with hepatitis c virus subtype 1b. | hepatitis c virus (hcv) subtype 1b, which infects approximately 70% of japanese carriers, is likely to be more eradicable by a telaprevir regimen than subtype 1a because of the higher genetic barrier of val(36) and arg(155) substitutions. the aims of this exploratory study were to evaluate the virological response and safety of 24-week oral administration of telaprevir alone in chronic hcv subtype 1b infection. fifteen treatment-naïve patients were treated with telaprevir 750 mg every 8 h for 24 ... | 2012 | 23383655 |